Last reviewed · How we verify
ART Intensification
At a glance
| Generic name | ART Intensification |
|---|---|
| Sponsor | Objectif Recherche Vaccins SIDA |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy (PHASE1)
- Efavirenz (EFV) Intensification (PHASE4)
- Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals (PHASE2)
- Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY (PHASE3)
- Effect of Dolutegravir Intensification on HIV-1 Reservoirs (PHASE2)
- Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND) (PHASE4)
- Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load (PHASE2)
- Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ART Intensification CI brief — competitive landscape report
- ART Intensification updates RSS · CI watch RSS
- Objectif Recherche Vaccins SIDA portfolio CI